Noninvasive Interventions Can Reduce Spine Pain Versus Usual Care
Small reductions in pain-related disability at three months for multidisciplinary biopsychosocial intervention, individualized postural therapy
Small reductions in pain-related disability at three months for multidisciplinary biopsychosocial intervention, individualized postural therapy
Higher prescription of oral morphine equivalents seen for adults with cerebral palsy, spina bifida across pain categories
Risdiplam is a survival motor neuron 2 splicing modifier.
Zolgensma is an adeno-associated virus vector-based gene therapy.
Apitegromab is a selective inhibitor of the inactive form of myostatin to block its activation in the muscle.
In Part 2 of the trial, patients 2-25 years of age received either risdiplam for 24 months or placebo for 12 months followed by risdiplam for 12 months.
The phase 3 SPR1NT trial is an ongoing open-label, single-arm study evaluating onasemnogene in presymptomatic patients (≤6 weeks of age) with a genetic diagnosis of SMA and 2 or 3 copies of survival motor neuron 2 gene.
This week we have remdesivir news; A new opioid and spinal muscular atrophy treatments are approved; A sublingual epinephrine treatment; And the latest on Biogen’s investigational Alzheimer disease treatment. Also, we have a brief summary of the other drugs in the pipeline from the past week.
Evrysdi is a survival motor neuron-2 (SMN2) splicing modifier.
New data from the phase 2 NURTURE trial evaluating nusinersen (Spinraza®; Biogen) demonstrate that presymptomatic patients with spinal muscular atrophy (SMA) continue to benefit from treatment for up to 4.8 years.